Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL9300827 | 0.87 | SNCA (0.43) | SNCATP53TSHRESRRGCYP19A1 | |
| Bromide SCHEMBL7028089 | 0.86 | SNCA (0.57) | SNCATSHRHIF1ALMNAALDH1A1 | |
| Bromide SCHEMBL16393752 | 0.86 | SNCA (0.53) | SNCATP53TSHRHIF1ARAB9A | |
| Bromide SCHEMBL39844 | 0.84 | SNCA (0.73) | SNCATSHREPHX1HIF1AALDH1A1 | |
| Bromide SCHEMBL6885198 | 0.84 | SNCA (0.46) | SNCATSHRHIF1ARAB9ABCHE | |
| Bromide SCHEMBL1840962 | 0.81 | SNCA (0.56) | SNCATSHRHIF1ARAB9AKDM1A | |
| Hydrochloric Acid SCHEMBL2446696 | 0.80 | SNCA (0.69) | SNCATSHREPHX1HIF1AALDH1A1 | |
| Bromide SCHEMBL163158 | 0.80 | SNCA (0.67) | SNCATSHREPHX1HIF1AALDH1A1 | |
| Iodide SCHEMBL9321342 | 0.80 | SNCA (0.69) | SNCATSHREPHX1HIF1AALDH1A1 | |
| Bromide SCHEMBL2447513 | 0.79 | SNCA (0.61) | SNCATSHRCYP19A1HIF1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-6824890-B2 | TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | NATIONAL SCIENCE FOUNDATION | 2003-03-20 | — | — | US | disclosed |
| WO-2001083410-A1 | SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-08 | — | — | WO | disclosed |
| US-5242945-A | Antiinflammatory | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0508690-A1 | Tetronic and thiotetronic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5134240-A | Malaria therapy | HOFFMANN-LAROCHE, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| US-4977184-A | Bicyclic peroxides compositions for and treatment of malaria therewith | HOFFMANN-LA ROCHE INC. (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | ACHE 3262/4885SNCA 4420/4885TP53 2204/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | ACHE 3262/4885SNCA 4420/4885TP53 2204/4885 |
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | PAX3, EPCAM, PAXBP1 | ACHE 1551/4885SNCA 561/4885TP53 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.